Assuming that future studies are able to show/confirm cost effectiveness and improved screening of aneuploidies, what challenges do you expect to face with the implementation of cffDNA screening? How do we educate OB-gyns about the availability of new screenings? Convince hospitals to make the switch? Approach insurance coverage?
Q&A has ended
Serena Chen, MD
Director of Reproductive Medicine at IRMS
- All Questions & Answers
- Question: Implementation of new screening?